At the news
? NEUTRALIMPACT 3/10 SC 13G filed Nov 6, 2026 at 14:38 ET
Barclays PLC disclosed a 5.48% passive stake in Aldeyra Therapeutics via a Schedule 13G filed November 6, 2026, representing 3,310,587 common shares held as of September 30, 2026. This is a new passive filer for Aldeyra, adding to prior 13G filings by AQR Capital Management, Perceptive Advisors, and Vanguard Group.
- Barclays PLC reported beneficial ownership of 3,310,587 common shares of Aldeyra Therapeutics
- Stake represents 5.48% of shares outstanding as of September 30, 2026
- Filing is a new Schedule 13G (not an amendment), certifying passive intent under Rule 13d-1(b)
- Barclays is a new 5%+ filer for Aldeyra; prior 13G filers include AQR Capital Management, Perceptive Advisors, and Vanguard Group
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access